ResearcherShanghai Jiao Tong UniversityActive in the last 2 years
Yehan Zhang
Matched on OpenAlex author ID A5039480241. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 3 papers
Papers 7
- The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy. Co-author DOI 10.1016/j.canlet.2026.218252↗
- Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post- neoadjuvant therapy" [Cancer Lett. (202… Co-author DOI 10.1016/j.canlet.2026.218298↗
- KRAS G12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.10.003↗
- A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy. Co-author DOI 10.1016/j.stem.2025.07.008↗
- Clinical functional proteomics of intercellular signalling in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08225-y↗
- Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101162↗
- Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Co-author DOI 10.1038/s41467-022-29857-6↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Gang Jin · 6 shared papers, 2022–2026 · strength 1.08
- Paper KRAS G12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. DOI 10.1016/j.ccell.2026.10.003↗
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Yunguang Li · 6 shared papers, 2022–2026 · strength 1.04
- Paper Clinical functional proteomics of intercellular signalling in pancreatic cancer. DOI 10.1038/s41586-024-08225-y↗
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Dong Gao · 5 shared papers, 2022–2026 · strength 0.89
- Paper KRAS G12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. DOI 10.1016/j.ccell.2026.10.003↗
- Paper Clinical functional proteomics of intercellular signalling in pancreatic cancer. DOI 10.1038/s41586-024-08225-y↗
- Paper A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of st… DOI 10.1016/j.stem.2025.07.008↗
- Xiaohan Shi · 4 shared papers, 2022–2026 · strength 0.65
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of st… DOI 10.1016/j.stem.2025.07.008↗
- Paper Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreati… DOI 10.1016/j.xcrm.2023.101162↗
- Kailian Zheng · 3 shared papers, 2022–2026 · strength 0.51
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Paper Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug… DOI 10.1038/s41467-022-29857-6↗
- Xiongfei Xu · 3 shared papers, 2022–2026 · strength 0.51
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Paper Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug… DOI 10.1038/s41467-022-29857-6↗
- Shiwei Guo · 3 shared papers, 2022–2025 · strength 0.45
- Paper A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of st… DOI 10.1016/j.stem.2025.07.008↗
- Paper Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreati… DOI 10.1016/j.xcrm.2023.101162↗
- Paper Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug… DOI 10.1038/s41467-022-29857-6↗
- Meilong Shi · 2 shared papers, 2026 · strength 0.39
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Lingyu Zhu · 2 shared papers, 2026 · strength 0.39
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Xiaoyi Yin · 2 shared papers, 2026 · strength 0.39
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Zhongjun Wu · 1 shared paper, 2026 · strength 0.23
- Lin Wang · 1 shared paper, 2026 · strength 0.23
- Yu Shi · 1 shared paper, 2025 · strength 0.20
- Peiwu Huang · 1 shared paper, 2025 · strength 0.20
- Min Wang · 1 shared paper, 2025 · strength 0.20
- Tony R. Hunter · 1 shared paper, 2025 · strength 0.20
- Renyi Qin · 1 shared paper, 2025 · strength 0.20
- Ruijun Tian · 1 shared paper, 2025 · strength 0.20
- Huan Wang · 1 shared paper, 2026 · strength 0.20
- Huan Wang · 1 shared paper, 2026 · strength 0.20
- Suizhi Gao · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.